A scoping review protocol for evaluating cost questionnaires aimed at measuring the household financial burden of food allergy

Ayel Luis R. Batac, Michael A. Golding, Kaitlyn A. Merrill, L. Mê-Linh, Andrew T. Fong, Peter S. Hsu, Christopher M. Warren, Priyanka Dadha, Elissa M. Abrams, Edmond S. Chan, Moshe Ben-Shoshan, Lucy A. Bilaver, Ruchi S. Gupta, Jodi A. Shroba, Juho E. Kivistö, Matthew J. Greenhawt, Mika J. Mäkelä, Antonella Muraro, Staffan Ahlstedt, Jennifer L.P. Protudjer*

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

1 Scopus citations
Original languageEnglish (US)
Pages (from-to)524-527
Number of pages4
JournalClinical and Experimental Allergy
Volume54
Issue number7
DOIs
StatePublished - Jul 2024

Funding

AB serves on the Manitoba and Saskatchewan Steering Committee for ImmUnity Canada, and is a scientist for the Government of Manitoba. The work presented here is conducted in his capacity as a researcher for the University of Manitoba and the Children's Hospital Research Institute of Manitoba. The views expressed herein are solely those of the author and do not represent the views of the Government of Manitoba or any of its departments and agencies. MG: none. AF: none. M\u2010LL: none. PD: none. KM: none. CW: none. EA holds the position of Section Head for Anaphylaxis and Food Allergy and is a Member of the Board for the Canadian Society of Allergy and Clinical Immunology. She is also the Chair of the Allergy Section of the Canadian Paediatrics Society. In addition, she is an employee of the Public Health Agency of Canada. The views expressed are her own and not those of the Public Health Agency of Canada. EC has received research support from DBV Technologies and has served on advisory boards for ALK\u2010Abell\u00F3, Alladapt Immunotherapeutics, Allergenis, AstraZeneca, Avir Pharma, Bausch Health, DBV Technologies, Kal\u00E9o, LEO Pharma, Medexus Pharmaceuticals, Miravo Healthcare, Pfizer and Sanofi Genzyme. In addition, he holds a position on the Executive Board of the Canadian Society of Allergy and Clinical Immunology and is a member of the healthcare advisory board for Food Allergy Canada. MB\u2010S serves on several advisory boards, including Food Allergy Canada, Novartis, Sanofi and Stallergenes Greer. He also reports personal fees from Bausch Health, Novartis, Sanofi and Stallergenes Greer. Additionally, he has received grants from Stallergenes Greer and has participated in clinical trials conducted by Aimmune Therapeutics, Novartis and Sanofi. LB has received research support from the National Institutes of Health, Novartis, Genentech, Yobee Care, Before Brands, Food Allergy Research and Education, the National Confectioners Association and Thermo Fisher Scientific. PH: none. RG receives research support from the National Institutes of Health (R21 ID # AI135705, R01 ID # AI130348, U01 ID # AI138907), Food Allergy Research & Education, Melchiorre Family Charitable Foundation, Sunshine Charitable Foundation, Walder Foundation, UnitedHealth Group, Thermo Fisher Scientific, Novartis and Genentech. She serves as a medical consultant/advisor for Aimmune Therapeutics, Allergenis, Food Allergy Research & Education, Genentech and Novartis. She has ownership interest in Yobee Care, Inc. Currently, she is employed by Ann & Robert H. Lurie Children's Hospital of Chicago and holds the position of Professor of Paediatrics and Medicine at the Northwestern University Feinberg School of Medicine. JS serves on the Advisory Board for both Genentech and Thermo Fisher Scientific. JK: none. MJG serves as a consultant for Aquestive and is a member of physician/medical advisory boards for various organizations, including ALK\u2010Abell\u00F3, Allergy Therapeutics, AstraZeneca, Bryn Pharma, DBV Technologies, Genentech, Novartis and Prota Therapeutics. Additionally, he is an unpaid member of the scientific advisory council for the National Peanut Board and the medical advisory board of the International Food Protein Induced Enterocolitis Syndrome Association. Furthermore, he is a member of the Brighton Collaboration Criteria Vaccine Anaphylaxis 2.0 working group and holds the position of senior associate editor for the Annals of Allergy, Asthma and Immunology. He is also a member of the Joint Taskforce on Allergy Practice Parameters. Moreover, he has received honorariums for lectures from Clinical Care Targeted Communications Group, International Meetings & Science, Medscape, Paradigm Medical Communications, Postgraduate Healthcare Education, Red Nucleus and multiple state/local allergy societies. MM: none. AM has received speaker's fees from Aimmune Therapeutics, DBV Technologies, Nestl\u00E9 Health Science and Nestl\u00E9 Purina Petcare. Additionally, she serves on the Advisory Boards of DBV Technologies, Novartis, Sanofi and Viatris. SA: none. JP is the Section Head for Allied Health, Co\u2010Lead of the Research Pillar for the Canadian Society of Allergy and Clinical Immunology; and a member of the steering committee for Canada's National Food Allergy Action Plan. She also reports consultancy work for Ajinomoto Cambrooke, ALK\u2010Abell\u00F3, Novartis and Nutricia. Funding for the development of the rapid review protocol was provided by J Protudjer's Start\u2010up Funds at the Children's Hospital Research Institute of Manitoba. The funding body had no influence on the study design; data collection, analysis and interpretation, writing of the protocol or the decision to submit for publication.

Keywords

  • burden
  • cost
  • financial
  • food allergy
  • health economics
  • household
  • questionnaire

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this